title: Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
abstract: OBJECTIVE
  To report outcomes of oral cavity cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy (chemoIMRT).
  
  
  METHODS
  Between 2001 and 2004, 21 patients with oral cavity squamous cell carcinoma underwent definitive chemoIMRT. Sites included were oral tongue (n = 9), floor of mouth (n = 6), buccal mucosa (n = 3), retromolar trigone (n = 2), and hard palate (n = 1). Most had stage III-IV disease (n = 20). The most common regimen was 5 days infusional 5-fluorouracil (600 mg/m(2)/d × 5 days), hydroxyurea (500 mg, PO BID), and 1.5 Gy twice-daily irradiation to 72 to 75 Gy.
  
  
  RESULTS
  The median follow-up for surviving patients was 60 months. Treatment failure occurred as follows: local-1, regional-1, and distant metastases-2. The 2- and 5-year estimates of locoregional progression-free survival, disease-free survival, and overall survival were 90% and 90%, 71% and 71%, and 76% and 76%, respectively. Late complications included osteoradionecrosis (3 patients, 14%).
  
  
  CONCLUSIONS
  Concurrent chemoIMRT results in promising locoregional control for oral cavity squamous cell carcinomas with acceptable toxicity.
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago, IL, USA.
authors.forename: Aaron W
authors.initials: AW
authors.lastname: Pederson
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Salama
authors.forename: Mary Ellen
authors.initials: ME
authors.lastname: Witt
authors.forename: Kerstin M
authors.initials: KM
authors.lastname: Stenson
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Blair
authors.forename: Everett E
authors.initials: EE
authors.lastname: Vokes
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Haraf
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000187:drug effects / Q000473:pathology*; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D009926:Organ Preservation; D011788:Quality of Life; D050397:Radiotherapy, Intensity-Modulated; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005472:Fluorouracil; D006918:Hydroxyurea